
    
      3-2,4 dimethoxybenzylidene will be compounded with a methyallose compound in doses of 150 and
      300 mg. The capsules will be administered singly and eventually bid to determine if sustained
      blood levels comparable to steady state blood levels seen in previous studies can be
      determined. Safety and EEG effects will be measured.
    
  